Latest revenue
$744.2M
as of 2026-03-31
Latest net income
$27.3M
as of 2026-03-31
Net margin
3.7%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- —
- Enterprise value
- —
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $3.92
- 52-wk low
- $1.58
- Beta
- —
- Shares out
- —
5-year trend
What this company does
Item 1. Business. General At Clover Health, our vision is to empower every physician with technology to identify, manage, and treat chronic diseases earlier. This results in earlier diagnosis and treatment, earlier disease management and more affordable and accessible care. Our strategy is to improve the care of our Medicare Advantage ("MA") members, develop wide physician networks, and provide technology to help empower physicians. Our proprietary software platform, Clover Assistant (licensed externally as Counterpart Assistant), supports clinical real-time decision making at the point of care by equipping the clinical with data and insights. This helps us execute our strategy by enabling…
AI summary unavailable — showing raw filing excerpt
Generated from CLOV's filing dated 2026-02-27
Key risks
Item 1A. Risk Factors. In the course of conducting our business operations, we are exposed to a variety of risks, any of which have affected or could materially adversely affect our business, financial condition, and results of operations. The market price of our common stock could decline, possibly significantly and permanently, if one or more of these risks and uncertainties occurs. Any factor described in this report or in any of our other SEC filings could by itself, or together with other factors, adversely affect our financial condition and results of operations. 21 Risks Related to Our Business and Industry We have incurred net losses in the past, and we may not be able to achieve or…
AI summary unavailable — showing raw filing excerpt
Generated from CLOV's filing dated 2026-02-27
Profitability
Operating margin
-4.4%
33.2%Net margin
-4.4%
41.7%Return on equity
-97.7%
11.0%Return on assets
-15.8%
113.5%Leverage
Debt / equity
1.33×
70.8%Long-term debt / equity
0.00×
100.0%Debt / assets
57.0%
30.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $744.2M | +62.9% | $27.3M | +2245.5% | 3.7% |
Q4 2025 2025-12-31 | $518.4M | +45.3% | — | — | — |
Q3 2025 2025-09-30 | $479.1M | +48.5% | — | — | — |
Q2 2025 2025-06-30 | $469.8M | +34.3% | — | — | — |
Q1 2025 2025-03-31 | $456.9M | +33.7% | $-1.3M | — | -0.3% |
Q4 2024 2024-12-31 | $356.9M | — | — | — | — |
Q3 2024 2024-09-30 | $322.6M | +7.1% | — | — | — |
Q2 2024 2024-06-30 | $349.9M | +11.3% | — | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Hospital & Medical Service Plans · SIC 6324
Your notes
Keep private notes on CLOV — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$1.1M
Insider selling
$2.0M
Net activity
−$979.2K
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CLOV
Institutional value
$136.4M
Total shares held
78.2M
Distinct holders
125
-66 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 31.8M | $56.0M | -440.3K (-1.4%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 17.0M | $29.9M | — | New |
| 3 | PNC Financial Services Group, Inc. | 3.8M | $6.6M | +83 (+0.0%) | Added |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.7M | $6.5M | — | New |
| 5 | DIMENSIONAL FUND ADVISORS LP | 3.4M | $6.0M | -216.5K (-6.0%) | Trimmed |
| 6 | VANGUARD FIDUCIARY TRUST CO | 2.8M | $4.9M | — | New |
| 7 | UBS Group AG | 1.8M | $3.1M | +452.5K (+34.4%) | Added |
| 8 | Bank of New York Mellon Corp | 1.1M | $2.0M | -34.6K (-3.0%) | Trimmed |
| 9 | JANE STREET GROUP, LLC | 1.0M | $1.8M | +454.9K (+77.6%) | Added |
| 10 | Invesco Ltd. | 1.0M | $1.8M | +165.2K (+19.1%) | Added |
| 11 | Nuveen, LLC | 935.5K | $1.6M | +52.0K (+5.9%) | Added |
| 12 | Swiss National Bank | 828.4K | $1.5M | +0 (+0.0%) | No change |
| 13 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 681.8K | $1.2M | -98.0K (-12.6%) | Trimmed |
| 14 | GROUP ONE TRADING LLC | 587.1K | $1.0M | -500.9K (-46.0%) | Trimmed |
| 15 | IMC-Chicago, LLC | 492.9K | $867.5K | -150.1K (-23.3%) | Trimmed |
| 16 | RHUMBLINE ADVISERS | 480.9K | $846.3K | -2.5K (-0.5%) | Trimmed |
| 17 | CHOREO, LLC | 386.6K | $680.4K | -320 (-0.1%) | Trimmed |
| 18 | DEUTSCHE BANK AG\ | 364.5K | $641.5K | -250.5K (-40.7%) | Trimmed |
| 19 | Legal & General Group Plc | 330.4K | $581.6K | -76.5K (-18.8%) | Trimmed |
| 20 | JPMORGAN CHASE & CO | 337.1K | $579.8K | +25.6K (+8.2%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CLOV's latest filing finishes processing.